Company news

Coherus Oncology, Inc. news in 2025

Coherus Oncology, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

December 8, 2025

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

November 7, 2025

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

November 6, 2025

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

November 6, 2025

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

October 30, 2025

Coherus Oncology to Participate in Upcoming Investor Conferences

October 23, 2025

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

October 3, 2025

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

August 7, 2025

Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®

August 6, 2025

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

July 31, 2025

Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics

May 30, 2025

Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)

May 27, 2025

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

May 5, 2025

Coherus to Participate in Upcoming Investor Conferences

May 1, 2025

Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

April 28, 2025

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise

April 14, 2025

Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes

April 1, 2025

Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

March 25, 2025

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

March 10, 2025

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

March 3, 2025

Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

January 21, 2025

Calls in 2025

Decks in 2025